Os Therapies
Rockville, Maryland, United States · Biopharma, Biotechnology, Healthcare
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.
Key facts
- Headquarters
- Rockville, Maryland, United States
- Employees
- 5
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (OSTX)
- Website
- ostherapies.com
- Company page
Recent activity at Os Therapies
- : OS THERAPIES (date of first sale on the SEC Form D)
- : OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer
- : OS THERAPIES
- : SEC 8-K (8.01): On November 11, 2026, OS Therapies UK Ltd., a subsidiary of OS Therapies Incorporated, received a VAT refund from HM Revenue and Customs amounting to £678,715.46 (approximately $900,000). This refund will be utilized to support the clinical development and regulatory readiness of their leading product candidate, Herlystic® (OST-HER2), aimed at preventing the recurrence of pulmonary metastatic osteosarcoma. Additionally, the FDA suspended its Commissioner’s National Priority Voucher program on November 12, 2026; however, this does not affect OS Therapies’ eligibility for the rare pediatric disease priority review voucher program. The developments signify a potential positive impact on the company's operations and strategic direction.
- : SEC 8-K (1.01):
- : SEC 8-K (5.02): Effective September 29, 2026, OS Therapies Incorporated appointed Francis (Frank) Knuettel II as Chief Financial Officer and Kerry Clem as Chief Commercial Officer. Concurrently, Christopher P. Acevedo ceased his role as CFO but will continue with the company in a consulting capacity. Knuettel brings over 30 years of executive experience from various industries including technology and life sciences. An employment agreement was established for Knuettel, which has an initial term of three years and includes a condition for term extension with a 180-day notice period. This leadership change aims to leverage Knuettel's extensive experience to navigate the company's future growth strategies.
- : SEC 8-K (8.01): On September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the SEC, part of its registration statement on Form S-3. This supplement pertains to the resale of up to 5,874,094 shares of common stock by the identified selling stockholders. The filing includes a legal opinion from Olshan Frome Wolosky LLP concerning the legality of the shares being offered. This event is significant as it indicates ongoing opportunities for shareholders to divest holdings, which could impact market liquidity and shareholder dynamics. The effective registration statement was previously filed on August 8, 2025, and declared effective on August 25, 2025.
- : SEC 8-K (5.02): On September 9, 2026, stockholders of OS Therapies Incorporated approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan during the Annual Meeting. This Amended and Restated Plan introduces significant updates aimed at optimizing the company's incentive structure for its executives and directors. The details of these amendments are thoroughly discussed in the Proxy Statement filed with the SEC on July 24, 2026. The approval reflects the company's commitment to enhancing its governance and compensatory practices to align with shareholder interests.
- : SEC 8-K (1.01): On August 21, 2026, OS Therapies Incorporated entered into a Material Definitive Agreement with Jefferies LLC, termed the Open Market Sale Agreement. This agreement allows the Company to offer and sell shares of its common stock through Jefferies in connection with the Company's at-the-market offering program. A prospectus supplement for this ATM Offering was also filed with the SEC on August 21, 2026, under the Company's shelf registration statement effective from August 25, 2025. This strategic move is aimed at raising capital and enhancing liquidity for OS Therapies, indicating positive growth prospects and investor engagement following the ongoing market conditions.
- : SEC 8-K (1.01): On August 10, 2026, OS Therapies Incorporated entered into a Securities Purchase Agreement to raise up to $10,000,000 through a private placement of senior secured convertible promissory notes. The first tranche, closed on August 10, 2026, raised $5,000,000, which included the issuance of notes totaling $5,405,405.42, alongside 600,000 shares of common stock, pre-funded warrants for 900,000 shares, and warrants for 1,500,000 shares. Additionally, a bridge convertible promissory note of $2,200,000, issued previously on August 2, 2026, automatically converted in accordance with the terms of the agreement, indicating a significant restructuring of financing. The proceeds are intended for funding clinical development and regulatory activities, signaling strategic growth plans for the Company.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Os Therapies funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Venture | $7.2M |
| Aug 2026 | Venture | $5.0M |
| Jun 2026 | Venture | $1.6M |
| Mar 2026 | Venture | $2.0M |
| Jan 2026 | Venture | $3.5M |
Leadership
- Theodore Search, Director
- John Ciccio, Director
- Joacim Borg, Director
- Colin Goddard, Director
- Paul Romness, Executive Officer, Director
- Knuettel, Chief Financial Officer
- Clem, Chief Commercial Officer
- Gerald Commissiong, Chief Business Officer
- Jutta Wanner, Executive Officer
- Robert Petit, Executive Officer
Verified email and direct lines for Os Therapies’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Os Therapies in the news
- OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - BioSpace (Oct 06, 2026)
- OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance - TMX Newsfile (Sep 02, 2026)
- An interim cancer-trial analysis found 71.2% three-year survival versus 45.8% in a historical group. - Stock Titan (Sep 08, 2026)
- OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms - Business Wire (Feb 24, 2025)
- 72.7% of treated patients survived three years, versus 45.8% in historical comparisons. - Stock Titan (Oct 06, 2026)
- OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Business Wire (Apr 09, 2025)
Companies similar to Os Therapies
- Lipella Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Retension Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Longboard Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Arbutus · Biopharma, Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Os Therapies: questions and answers
What does Os Therapies do?
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.
Where is Os Therapies headquartered?
Os Therapies is headquartered in Rockville, Maryland, United States.
How many employees does Os Therapies have?
Os Therapies has about 5 employees.
Has Os Therapies raised funding?
Yes. Fundz has recorded 5 funding events for Os Therapies. The most recent, $7.2M, was in Oct 2026.
What is the latest news on Os Therapies?
On Oct 15, 2026, OS THERAPIES
Is Os Therapies a public company?
Yes. Os Therapies is publicly traded under the ticker OSTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy